Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine

References

• MarisJMRecent advances in neuroblastomaN Engl J Med2010362232202221120558371
   PubMed Web of Science ®Google Scholar
• ModakSCheungNKNeuroblastoma: Therapeutic strategies for a clinical enigmaCancer Treat Rev201036430731720227189
   PubMed Web of Science ®Google Scholar
• ModakSCheungNKDisialoganglioside directed immunotherapy of neuroblastomaCancer Invest2007251677717364560
   PubMed Web of Science ®Google Scholar
• YuALGilmanALOzkaynakMFAnti-GD2 antibody with GMCSF, interleukin-2, and isotretinoin for neuroblastomaN Engl J Med2010363141324133420879881
   PubMed Web of Science ®Google Scholar
• CheungNKSowersRVickersAJCheungIYKushnerBHGorlickRFCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorJ Clin Oncol200624182885289016682723
   PubMed Web of Science ®Google Scholar
• MorozVMachinDFaldumAChanges over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectEur J Cancer201147456157121112770
   PubMed Web of Science ®Google Scholar
• CaneteAGerrardMRubieHPoor survival for infants with MYCN-amplif ied metastatic neuroblastoma despite intensif ied treatment: the International Society of Paediatric Oncology European Neuroblastoma ExperienceJ Clin Oncol20092771014101919171715
   PubMed Web of Science ®Google Scholar
• De BernardiBNicolasBBoniLDisseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for NeuroblastomaJ Clin Oncol20032181592160112697885
   PubMed Web of Science ®Google Scholar
• MatthayKKVillablancaJGSeegerRCTreatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer GroupN Engl J Med1999341161165117310519894
   PubMed Web of Science ®Google Scholar
• LondonWBCastelVMonclairTClinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectJ Clin Oncol201129243286329221768459
   PubMed Web of Science ®Google Scholar
• SchillingFHSpixCBertholdFNeuroblastoma screening at one year of ageN Engl J Med2002346141047105311932471
   PubMed Web of Science ®Google Scholar
• WoodsWGGaoRNShusterJJScreening of infants and mortality due to neuroblastomaN Engl J Med2002346141041104611932470
   PubMed Web of Science ®Google Scholar
• MarisJMHogartyMDBagatellRCohnSLNeuroblastomaLancet200736995792106212017586306
   PubMed Web of Science ®Google Scholar
• CarenHAbelFKognerPMartinssonTHigh incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumoursBiochem J2008416215315918990089
   PubMed Web of Science ®Google Scholar
• GeorgeRESandaTHannaMActivating mutations in ALK provide a therapeutic target in neuroblastomaNature2008455721597597818923525
   PubMed Web of Science ®Google Scholar
• MosseYPLaudenslagerMLongoLIdentification of ALK as a major familial neuroblastoma predisposition geneNature2008455721593093518724359
   PubMed Web of Science ®Google Scholar
• NakagawaraAAzarCGScavardaNJBrodeurGMExpression and function of TRK-B and BDNF in human neuroblastomasMol Cell Biol19941417597678264643
   PubMed Web of Science ®Google Scholar
• NorrisREMinturnJEBrodeurGMMarisJMAdamsonPCPreclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastomaCancer Chemother Pharmacol20116861469147521484309
   PubMed Web of Science ®Google Scholar
• MinturnJEEvansAEVillablancaJGPhase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium studyCancer Chemother Pharmacol20116841057106521340605
   PubMed Web of Science ®Google Scholar
• LiZThieleCJTargeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathwayExpert Opin Ther Targets200711121611162118020981
   PubMed Web of Science ®Google Scholar
• SarteletHOlignyLLVassalGAKT pathway in neuroblastoma and its therapeutic implicationExpert Rev Anticancer Ther20088575776918471048
   PubMed Web of Science ®Google Scholar
• ManningBDCantleyLCAKT/PKB signaling: navigating downstreamCell200712971261127417604717
   PubMed Web of Science ®Google Scholar
• ShawRJCantleyLCRas, PI(3)K and mTOR signalling controls tumour cell growthNature2006441709242443016724053
   PubMed Web of Science ®Google Scholar
• BrazilDPParkJHemmingsBAPKB binding proteins. Getting in on the AktCell2002111329330312419241
   PubMed Web of Science ®Google Scholar
• Blume-JensenPHunterTOncogenic kinase signallingNature2001411683535536511357143
   PubMed Web of Science ®Google Scholar
• FrankeTFYangSIChanTOThe protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinaseCell19958157277367774014
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-Kinase AKT pathway in human cancerNat Rev Cancer20022748950112094235
   PubMed Web of Science ®Google Scholar
• CullyMYouHLevineAJMakTWBeyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNat Rev Cancer20066318419216453012
   PubMed Web of Science ®Google Scholar
• BellacosaAKumarCCDi CristofanoATestaJRActivation of AKT kinases in cancer: implications for therapeutic targetingAdv Cancer Res200594298616095999
   PubMed Web of Science ®Google Scholar
• EngelmanJALuoJCantleyLCThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNat Rev Genet20067860661916847462
   PubMed Web of Science ®Google Scholar
• HennessyBTSmithDLRamPTLuYMillsGBExploiting the PI3K/AKT pathway for cancer drug discoveryNat Rev Drug Discov2005412988100416341064
   PubMed Web of Science ®Google Scholar
• LuoJManningBDCantleyLCTargeting the PI3K-Akt pathway in human cancer: rationale and promiseCancer Cell20034425726214585353
   PubMed Web of Science ®Google Scholar
• CantleyLCNeelBGNew insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathwayProc Natl Acad Sci U S A19999684240424510200246
   PubMed Web of Science ®Google Scholar
• OpelDPorembaCSimonTDebatinKMFuldaSActivation of Akt predicts poor outcome in neuroblastomaCancer Res200767273574517234785
   PubMed Web of Science ®Google Scholar
• Izycka-SwieszewskaEDrozynskaERzepkoRAnalysis of PI3K/ AKT/mTOR signalling pathway in high risk neuroblastic tumoursPol J Pathol201061419219821290341
   PubMed Web of Science ®Google Scholar
• JohnsenJISegerstromLOrregoAInhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivoOncogene200827202910292218026138
   PubMed Web of Science ®Google Scholar
• SarteletHOhtaSBarretteSHigh level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastomaHistopathology201056560761620459571
   PubMed Web of Science ®Google Scholar
• LiZJaboinJDennisPAThieleCJGenetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/ TrkB rescue of neuroblastoma cells from chemotherapy-induced cell deathCancer Res20056562070207515781614
   PubMed Web of Science ®Google Scholar
• KimBvan GolenCMFeldmanELInsulin-like growth factor-I signaling in human neuroblastoma cellsOncogene200423113014114712218
   PubMed Web of Science ®Google Scholar
• CoulterDWBlattJD’ErcoleAJMoats-StaatsBMIGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growthAnticancer Res2008283A1509151618630505
   PubMed Web of Science ®Google Scholar
• EvangelopoulosMEWeisJKruttgenASignalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFROncogene200524203309331815735700
   PubMed Web of Science ®Google Scholar
• ChiuBMirkinBMadonnaMBMitogenic and apoptotic actions of epidermal growth factor on neuroblastoma cells are concentration- dependentJ Surg Res2006135220921216872636
   PubMed Web of Science ®Google Scholar
• ServideiTRiccardiASanguinettiMDominiciCRiccardiRIncreased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivationJ Cell Physiol2006208122022816575905
   PubMed Web of Science ®Google Scholar
• BeierleEANagaramADaiWIyengarMChenMKVEGF-mediated survivin expression in neuroblastoma cellsJ Surg Res20051271212815882878
   PubMed Web of Science ®Google Scholar
• NganESSitFYLeeKImplications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progressionClin Cancer Res200713386887517289879
   PubMed Web of Science ®Google Scholar
• BeppuKNakamuraKLinehanWMRapisardaAThieleCJTopotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cellsCancer Res200565114775478115930297
   PubMed Web of Science ®Google Scholar
• MookherjeePQuintanillaRRohMSZmijewskaAAJopeRSJohnsonGVMitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell deathJ Cell Biochem2007102119621017340627
   PubMed Web of Science ®Google Scholar
• FrancoisFGrimesMLPhosphorylation-dependent Akt cleavage in neural cell in vitro reconstitution of apoptosisJ Neurochem19997341773177610501228
   PubMed Web of Science ®Google Scholar
• DattaSRBrunetAGreenbergMECellular survival: a play in three AktsGenes Dev199913222905292710579998
   PubMed Web of Science ®Google Scholar
• DozzaBSmithMAPerryGTabatonMStrocchiPRegulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cellsJ Neurochem20048951224123215147515
   PubMed Web of Science ®Google Scholar
• ZhouXWWinbladBGuanZPeiJJInteractions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cellsJ Alzheimers Dis200917492993719542610
   PubMed Web of Science ®Google Scholar
• LinRJLinYCChenJmicroRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastomaCancer Res201070207841785020805302
   PubMed Web of Science ®Google Scholar
• FoleyNHBrayIMTivnanAMicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2Mol Cancer201098320409325
   PubMed Web of Science ®Google Scholar
• ChenYTakitaJChoiYLOncogenic mutations of ALK kinase in neuroblastomaNature2008455721597197418923524
   PubMed Web of Science ®Google Scholar
• Janoueix-LeroseyILequinDBrugieresLSomatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature2008455721596797018923523
   PubMed Web of Science ®Google Scholar
• HoebeeckJMichelsEPattynFAberrant methylation of candidate tumor suppressor genes in neuroblastomaCancer Lett2009273233634618819746
   PubMed Web of Science ®Google Scholar
• MunozJLazcozPIndaMMHomozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell linesInt J Cancer2004109567367914999773
   PubMed Web of Science ®Google Scholar
• KimSKangJQiaoJThomasRPEversBMChungDHPhosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomasJ Pediatr Surg200439451652115065019
   PubMed Web of Science ®Google Scholar
• BroniszAGajkowskaBDomanska-JanikKPKC and Raf-1 inhibition- related apoptotic signalling in N2a cellsJ Neurochem20028161176118412068066
   PubMed Web of Science ®Google Scholar
• ZhuWBijurGNStylesNALiXRegulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cellsBrain Res Mol Brain Res20041261455615207915
   PubMedGoogle Scholar
• ShuklaNNAmeurNYilmazIOncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling PathwaysClin Cancer Res2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• WeinsteinIBJoeAKMechanisms of disease: Oncogene addiction – a rationale for molecular targeting in cancer therapyNat Clin Pract Oncol20063844845716894390
   PubMedGoogle Scholar
• BarnettSFBilodeauMTLindsleyCWThe Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validationCurr Top Med Chem20055210912515853641
   PubMed Web of Science ®Google Scholar
• PalSKReckampKYuHFiglinRAAkt inhibitors in clinical development for the treatment of cancerExpert Opin Investig Drugs2010191113551366
   PubMed Web of Science ®Google Scholar
• HilgardPKlennerTStekarJNossnerGKutscherBEngelJD-21266, a new heterocyclic alkylphospholipid with antitumour activityEur J Cancer19973334424469155530
   PubMed Web of Science ®Google Scholar
• VinkSRvan BlitterswijkWJSchellensJHVerheijMRationale and clinical application of alkylphospholipid analogues in combination with radiotherapyCancer Treat Rev200733219120217287087
   PubMed Web of Science ®Google Scholar
• KondapakaSBSinghSSDasmahapatraGPSausvilleEARoyKKPerifosine, a novel alkylphospholipid, inhibits protein kinase B activationMol Cancer Ther20032111093110314617782
   PubMed Web of Science ®Google Scholar
• GillsJJDennisPAPerifosine: update on a novel Akt inhibitorCurr Oncol Rep200911210211019216841
   PubMed Web of Science ®Google Scholar
• LoPiccoloJGranvilleCAGillsJJDennisPATargeting Akt in cancer therapyAnticancer Drugs200718886187417667591
   PubMed Web of Science ®Google Scholar
• RuiterGAZerpSFBartelinkHvan BlitterswijkWJVerheijMAnti- cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathwayAnticancer Drugs200314216717312569304
   PubMed Web of Science ®Google Scholar
• LiXLuworRLuYLiangKFanZEnhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cellsOncogene200625452553516170346
   PubMed Web of Science ®Google Scholar
• ChiariniFDel SoleMMongiorgiSThe novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanismLeukemia20082261106111618385752
   PubMed Web of Science ®Google Scholar
• ElrodHALinYDYuePThe alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathwayMol Cancer Ther2007672029203817604333
   PubMed Web of Science ®Google Scholar
• TazzariPLTabelliniGRicciFSynergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cellsCancer Res200868229394940319010914
   PubMed Web of Science ®Google Scholar
• FestucciaCGravinaGLMuziPAkt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitorsProstate200868996597418361408
   PubMed Web of Science ®Google Scholar
• FlorykDThompsonTCPerifosine induces differentiation and cell death in prostate cancer cellsCancer Lett2008266221622618395973
   PubMed Web of Science ®Google Scholar
• NyakernMCappelliniAMantovaniIMartelliAMSynergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathwaysMol Cancer Ther2006561559157016818515
   PubMed Web of Science ®Google Scholar
• FeiHRChenGWangJMWangFZPerifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylationCytotechnology201062544946020842425
   PubMed Web of Science ®Google Scholar
• EngelJBSchonhalsTHauslerSInduction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancersArch Gynecol Obstet2011283360361020405296
   PubMed Web of Science ®Google Scholar
• KumarAFillmoreHLKadianRBroaddusWCTyeGWVan MeterTEThe alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastomaMol Cancer Res20097111813182119887560
   PubMed Web of Science ®Google Scholar
• CatleyLHideshimaTChauhanDAlkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma modelExp Hematol20073571038104617588472
   PubMed Web of Science ®Google Scholar
• HideshimaTCatleyLYasuiHPerifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsBlood2006107104053406216418332
   PubMed Web of Science ®Google Scholar
• HideshimaTCatleyLRajeNInhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsBr J Haematol2007138678379117760810
   PubMed Web of Science ®Google Scholar
• MomotaHNerioEHollandECPerifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivoCancer Res200565167429743516103096
   PubMed Web of Science ®Google Scholar
• LeleuXJiaXRunnelsJThe Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood2007110134417442617761832
   PubMed Web of Science ®Google Scholar
• HennessyBTLuYPoradosuEPharmacodynamic markers of perifosine efficacyClin Cancer Res200713247421743118094426
   PubMed Web of Science ®Google Scholar
• BecherOJHambardzumyanDWalkerTRPreclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem gliomaCancer Res20107062548255720197468
   PubMed Web of Science ®Google Scholar
• HambardzumyanDBecherOJRosenblumMKPandolfiPPManova-TodorovaKHollandECPI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivoGenes Dev200822443644818281460
   PubMed Web of Science ®Google Scholar
• Van UmmersenLBingerKVolkmanJA phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancerClin Cancer Res200410227450745615569974
   PubMed Web of Science ®Google Scholar
• CrulMRosingHde KlerkGJPhase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumoursEur J Cancer200238121615162112142051
   PubMed Web of Science ®Google Scholar
• UngerCBerdelWHanauskeARSindermannHEngelJMrossKFirst-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumoursEur J Cancer201046592092520079628
   PubMed Web of Science ®Google Scholar
• BaileyHHMahoneyMREttingerDSPhase II study of daily oral perifosine in patients with advanced soft tissue sarcomaCancer2006107102462246717058289
   PubMed Web of Science ®Google Scholar
• GhobrialIMRoccaroAHongFClinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemiaClin Cancer Res20101631033104120103671
   PubMed Web of Science ®Google Scholar
• BendellJCNemunaitisJVukeljaSJRandomized placebo- controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancerJ Clin Oncol201129334394440021969495
   PubMed Web of Science ®Google Scholar
• RichardsonPGWolfJJakubowiakAPerifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialJ Clin Oncol201129324243424921990396
   PubMed Web of Science ®Google Scholar
• LiZTanFLiewehrDJSteinbergSMThieleCJIn vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosineJ Natl Cancer Inst20101021175877020463309
   PubMed Web of Science ®Google Scholar
• LiZOhDYNakamuraKThieleCJPerifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivoCancer2011117235412542221590687
   PubMed Web of Science ®Google Scholar
• DasmahapatraGPDidolkarPAlleyMCGhoshSSausvilleEARoyKKIn vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell linesClin Cancer Res200410155242525215297428
   PubMed Web of Science ®Google Scholar
• RahmaniMReeseEDaiYCoadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen speciesCancer Res20056562422243215781658
   PubMed Web of Science ®Google Scholar
• DavidESinhaRChenJSunSYKaufmanJLLonialSPerifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptorsClin Cancer Res200814165090509818698026
   PubMed Web of Science ®Google Scholar
• HustonALeleuXJiaXTargeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentClin Cancer Res200814386587418245550
   PubMed Web of Science ®Google Scholar
• PitterKLGalbanCJGalbanSPerifosine and CCI 779 cooperate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastomaPLoS One201161e1454521267448
   PubMed Web of Science ®Google Scholar
• EngelJBHonigASchonhalsTPerifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylationEur J Obstet Gynecol Reprod Biol20081411646918687514
   PubMed Web of Science ®Google Scholar
• PapaVTazzariPLChiariniFProapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cellsLeukemia200822114716017928881
   PubMed Web of Science ®Google Scholar
• BecherOJHambardzumyanDWalkerTRPreclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem gliomaCancer Res20107062548255720197468
   PubMed Web of Science ®Google Scholar
• IyerREvansAEQiXLestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastomaClin Cancer Res20101651478148520179224
   PubMed Web of Science ®Google Scholar
• BecherOJTrippettTKolesarJPhase I study of single-agent perifosine for recurrent pediatric solid tumors [abstract]J Clin Oncol20102815s9540
   Google Scholar
• BecherOJKhakooYModakSPhase I study of single agent perifosine for recurrent pediatric solid tumors [abstract]Advances in Neuroblastoma Research2010POC2
   Google Scholar
• Rodrik-OutmezguineVSChandarlapatySPaganoNCmTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signalingCancer Discov20111324825922140653
   PubMed Web of Science ®Google Scholar
• SpuntSLGruppSAVikTAPhase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumorsJ Clin Oncol201129212933294021690471
   PubMed Web of Science ®Google Scholar
• GeoergerBKieranMWGruppSPhase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaEur J Cancer201248225326222033322
   PubMed Web of Science ®Google Scholar